Display options
Cite
Wu PC, Wu VC, Lin CJ, et al. Meglitinides increase the risk of hypoglycemia in diabetic patients with advanced chronic kidney disease: a nationwide, population-based study. Oncotarget. 2017;8(44):78086-78095doi: 10.18632/oncotarget.17475.
Wu, P. C., Wu, V. C., Lin, C. J., Pan, C. F., Chen, C. Y., Huang, T. M., Wu, C. H., Chen, L., Wu, C. J. (2017). Meglitinides increase the risk of hypoglycemia in diabetic patients with advanced chronic kidney disease: a nationwide, population-based study. Oncotarget, 8(44), 78086-78095. https://doi.org/10.18632/oncotarget.17475
Wu, Pei-Chen, et al. "Meglitinides increase the risk of hypoglycemia in diabetic patients with advanced chronic kidney disease: a nationwide, population-based study." Oncotarget vol. 8,44 (2017): 78086-78095. doi: https://doi.org/10.18632/oncotarget.17475
Wu PC, Wu VC, Lin CJ, Pan CF, Chen CY, Huang TM, Wu CH, Chen L, Wu CJ. Meglitinides increase the risk of hypoglycemia in diabetic patients with advanced chronic kidney disease: a nationwide, population-based study. Oncotarget. 2017 Apr 27;8(44):78086-78095. doi: 10.18632/oncotarget.17475. eCollection 2017 Sep 29. PMID: 29100450; PMCID: PMC5652839.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 Apr 27;8(44):78086-78095. doi: 10.18632/oncotarget.17475. eCollection 2017 Sep 29.

Meglitinides increase the risk of hypoglycemia in diabetic patients with advanced chronic kidney disease: a nationwide, population-based study.

Oncotarget

Pei-Chen Wu, Vin-Cent Wu, Cheng-Jui Lin, Chi-Feng Pan, Chih-Yang Chen, Tao-Min Huang, Che-Hsiung Wu, Likwang Chen, Chih-Jen Wu,

Affiliations

  1. Division of Nephrology, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan.
  2. Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.
  3. Division of Nephrology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  4. Department of Medicine, Mackay Medical College, Taipei, Taiwan.
  5. Mackay Junior College of Medicine, Nursing and Management, Taipei, Taiwan.
  6. Department of Internal Medicine, National Taiwan University Hospital Yun-Lin Branch, Douliou, Taiwan.
  7. Division of Nephrology, Taipei Buddhist Tzu Chi General Hospital, Buddhist Tzu Chi University, Taipei, Taiwan.
  8. Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Taiwan.
  9. Graduate Institute of Medical Sciences and Department of Pharmacology, College of Medicine, Taipei Medical University, Taipei, Taiwan.
  10. Department of Medical Research, China Medical University Hospital, China Medical University, Taichung, Taiwan.

PMID: 29100450 PMCID: PMC5652839 DOI: 10.18632/oncotarget.17475

Abstract

The safety of short-acting meglitinides in diabetic patients with advanced chronic kidney disease (CKD) has not been widely reported. Diabetic patients with advanced CKD who had a serum creatinine level of > 6 mg/dL a hematocrit level of ≦ 28% and received erythropoiesis-stimulating agent treatment between 2000 and 2010, were included in this nationwide study in Taiwan. The outcomes of interest were defined as hypoglycemia and long-term mortality. The risks of hypoglycemia and death were analyzed using Cox proportional hazards models, with end-stage renal disease and anti-diabetic drugs as time-dependent variables. Fresh users and matched non-users of meglitinides (both

Keywords: chronic kidney disease; diabetes mellitus; hypoglycemia; meglitinide; mortality

Conflict of interest statement

CONFLICTS OF INTEREST The authors declare no conflicts of interest.

References

  1. Clin J Am Soc Nephrol. 2009 Jun;4(6):1121-7 - PubMed
  2. Clin J Am Soc Nephrol. 2014 Apr;9(4):638-40 - PubMed
  3. Am J Kidney Dis. 2014 Jan;63(1 Suppl):A7 - PubMed
  4. Am J Kidney Dis. 2012 Nov;60(5):850-86 - PubMed
  5. Kidney Int. 2011 Dec;80(11):1222-30 - PubMed
  6. Diabetes Care. 2013 Apr;36(4):894-900 - PubMed
  7. Aging Dis. 2015 Mar 10;6(2):156-67 - PubMed
  8. J Clin Epidemiol. 2014 Oct;67(10):1139-49 - PubMed
  9. Crit Care Med. 2009 Nov;37(11):2939-45 - PubMed
  10. Diabetes Care. 2003 Jul;26(7):2075-80 - PubMed
  11. Diabetes Care. 2004 Jun;27(6):1265-70 - PubMed
  12. N Engl J Med. 2009 Jan 8;360(2):129-39 - PubMed
  13. J Chronic Dis. 1987;40(5):373-83 - PubMed
  14. Semin Dial. 2004 Sep-Oct;17(5):365-70 - PubMed
  15. Diabetes Care. 2003 Jul;26(7):2063-8 - PubMed
  16. J Clin Endocrinol Metab. 2011 Oct;96(10):3175-83 - PubMed
  17. Clin J Am Soc Nephrol. 2015 Mar 6;10(3):353-62 - PubMed
  18. Vasc Health Risk Manag. 2014 Jun 13;10:341-52 - PubMed
  19. Cochrane Database Syst Rev. 2007 Apr 18;(2):CD004654 - PubMed
  20. Cardiovasc Diabetol. 2012 Oct 06;11:122 - PubMed
  21. Diabetes Care. 2010 Jun;33(6):1389-94 - PubMed
  22. Stat Med. 2008 Aug 30;27(19):3805-16 - PubMed
  23. Rev Cardiovasc Med. 2013;14(2-4):e107-22 - PubMed
  24. Curr Drug Metab. 2011 Jan;12(1):57-69 - PubMed
  25. Hormones (Athens). 2013 Oct-Dec;12(4):483-94 - PubMed
  26. N Engl J Med. 2008 Jun 12;358(24):2560-72 - PubMed
  27. Crit Care. 2013 Oct 11;17(5):R231 - PubMed
  28. Proc Natl Acad Sci U S A. 2014 Mar 11;111(10):3817-22 - PubMed
  29. J Bone Miner Res. 2014 Mar;29(3):676-84 - PubMed
  30. J Am Heart Assoc. 2014 Jul 15;3(4):null - PubMed
  31. Lancet. 2010 Aug 7;376(9739):419-30 - PubMed
  32. Sci Rep. 2016 Aug 16;6:26335 - PubMed
  33. Arch Med Sci. 2013 Oct 31;9(5):936-43 - PubMed
  34. Eur J Clin Pharmacol. 2001 May;57(2):147-52 - PubMed
  35. Clin Nephrol. 2003 Aug;60(2):90-5 - PubMed
  36. Am J Kidney Dis. 2014 Feb;63(2 Suppl 2):S22-38 - PubMed
  37. J Am Soc Nephrol. 2008 May;19(5):841-3 - PubMed
  38. PLoS One. 2015 Jun 10;10(6):e0126427 - PubMed
  39. Pharmacoepidemiol Drug Saf. 2011 Mar;20(3):236-42 - PubMed
  40. J Am Soc Nephrol. 2014 Mar;25(3):595-605 - PubMed
  41. Clin Pharmacol Ther. 2000 Jan;67(1):7-15 - PubMed

Publication Types